Prab: CSV import

2024-03-06T04:47:28Z

CSV import

New page

[[File:Flesinoxan.png|thumb|{{PAGENAME}}]]<br>'''Flesinoxan''' is a [[quinuclidinyl benzamide]] derivative that acts as a potent and selective [[5-HT1A receptor]] [[agonist]]. It was originally developed by [[Pfizer]] in the 1980s for the treatment of [[hypertension]] and [[migraine]], but was later abandoned and is now used primarily in scientific research.

== History ==

[[Flesinoxan]] was first synthesized by [[Pfizer]] in the 1980s as part of a research program aimed at developing new treatments for [[hypertension]] and [[migraine]]. Early clinical trials showed promising results, but the drug was ultimately not brought to market for these indications. Today, it is used primarily in scientific research, particularly in studies investigating the role of the [[5-HT1A receptor]] in various physiological and pathological processes.

== Pharmacology ==

[[Flesinoxan]] is a potent and selective [[5-HT1A receptor]] [[agonist]]. It binds to the [[5-HT1A receptor]] with high affinity, and activates the receptor to produce its biological effects. The [[5-HT1A receptor]] is a type of [[serotonin receptor]] that is widely distributed in the brain and plays a key role in the regulation of mood, anxiety, and the stress response.

== Clinical Use ==

While [[Flesinoxan]] was originally developed for the treatment of [[hypertension]] and [[migraine]], it is now used primarily in scientific research. It is often used as a tool to investigate the role of the [[5-HT1A receptor]] in various physiological and pathological processes, including mood disorders, anxiety disorders, and the stress response.

== See Also ==

* [[5-HT1A receptor]]
* [[Serotonin receptor]]
* [[Pfizer]]

== References ==

<references />

[[Category:Pharmacology]]
[[Category:Serotonin receptor agonists]]
[[Category:Abandoned drugs]]
{{Pharmacology-stub}}

Flesinoxan - Revision history

Prab: CSV import